Gilead and the Galapagos' Fergtini drug RA trial was successful

Gilead and the Galapagos have released promising data from another group of JAK inhibitors, filgotinib, this time rheumatoid arthritis.
the company said a few days after the success of the strong spina bifiditis drug Phase II, a Phase III trial also met the main goal of rheumatoid arthritis patients who had previously failed to respond to biologic treatment or were insatiable to biologics.
In the FINCH 2 study, there was a significant increase in the proportion of patients treated with filgotinib who received the American Rheumatology Society's 20 percent response (ACR20) in week 12, with results of 66 percent (200 mg dose) and 57.5 percent (100 mg dose), respectively, compared to 31 percent for placebo.
In addition, in weeks 12 and 24, patients who received ACR50 and ACR70 had significantly higher rates of disease activity and clinical remission than those who received a placebo, the company noted.
safety, the drug was reported to be well-to-do, with adverse events and serious adverse events occurring after treatment being "minor or moderate in severity." Severe adverse events in the placebo group, 100mg group and 200mg group were 3.4%, 5.2% and 4.1%, respectively.
"These initial Phase III data support the potential of filgotinib, combined with the drugs chosen to regulate disease, to help active rheumatoid arthritis patients who do not adequately respond to current biodemotic modifiers," said John McHutchison, Chief Scientific Officer, Gilead's head of research and development. " (This web article) is